Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesenchymal stem cells (MSCs) developed by the Sixth Affiliated Hospital of Sun Yat-sen University are an investigational cell therapy being evaluated for the treatment of refractory perianal fistulas in patients with Crohn's disease. Administered via local injection into the fistula tract and surrounding tissue, these MSCs exert therapeutic effects through immunomodulation and the secretion of pro-healing factors. They aim to reduce local inflammation and promote the regeneration of damaged tissues, facilitating the closure of complex fistulas that are often resistant to conventional medical and surgical treatments. The therapy is typically administered following routine drainage surgery to optimize the healing environment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mesenchymal stem cells (Sixth Affiliated Hospital, Sun Yat-sen University).